These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 19968575)

  • 1. Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.
    Kwara A; Ramachandran G; Swaminathan S
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):55-68. PubMed ID: 19968575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
    Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.
    Sathia L; Obiorah I; Taylor G; Kon O; O'Donoghue M; Gibbins S; Walsh J; Winston A
    AIDS Res Hum Retroviruses; 2008 Jul; 24(7):897-901. PubMed ID: 18671475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa.
    Cohen K; Grant A; Dandara C; McIlleron H; Pemba L; Fielding K; Charalombous S; Churchyard G; Smith P; Maartens G
    Antivir Ther; 2009; 14(5):687-95. PubMed ID: 19704172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
    Stöhr W; Back D; Dunn D; Sabin C; Winston A; Gilson R; Pillay D; Hill T; Ainsworth J; Pozniak A; Leen C; Bansi L; Fisher M; Orkin C; Anderson J; Johnson M; Easterbrook P; Gibbons S; Khoo S; ;
    Antivir Ther; 2008; 13(5):675-85. PubMed ID: 18771051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.
    Kwara A; Yang H; Antwi S; Enimil A; Gillani FS; Dompreh A; Ortsin A; Opoku T; Bosomtwe D; Sarfo A; Wiesner L; Norman J; Alghamdi WA; Langaee T; Peloquin CA; Court MH; Greenblatt DJ
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
    Boulle A; Van Cutsem G; Cohen K; Hilderbrand K; Mathee S; Abrahams M; Goemaere E; Coetzee D; Maartens G
    JAMA; 2008 Aug; 300(5):530-9. PubMed ID: 18677025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.
    Naidoo A; Chirehwa M; McIlleron H; Naidoo K; Essack S; Yende-Zuma N; Kimba-Phongi E; Adamson J; Govender K; Padayatchi N; Denti P
    J Antimicrob Chemother; 2017 May; 72(5):1441-1449. PubMed ID: 28175315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study.
    Sinha S; Raghunandan P; Chandrashekhar R; Sharma SK; Kumar S; Dhooria S; Ekka M; Velpandian T; Ranjan S; Ahmad H; Samantaray JC; Venkatesh S; Rewari BB; Khan NH; Pandey RM
    BMC Infect Dis; 2013 Oct; 13():482. PubMed ID: 24134449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?
    Orrell C; Cohen K; Conradie F; Zeinecker J; Ive P; Sanne I; Wood R
    Antivir Ther; 2011; 16(4):527-34. PubMed ID: 21685540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
    Chang SY; Lin SW; Hung CC
    Clin Infect Dis; 2009 Nov; 49(9):1452-3; author reply 1453-4. PubMed ID: 19824849
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.
    McIlleron HM; Schomaker M; Ren Y; Sinxadi P; Nuttall JJ; Gous H; Moultrie H; Eley B; Merry C; Smith P; Haas DW; Maartens G
    AIDS; 2013 Jul; 27(12):1933-40. PubMed ID: 24180002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients.
    Ramachandran G; Kumar AK; Ponnuraja C; Ramesh K; Rajesh L; Chandrasekharan C; Swaminathan S
    Indian J Med Res; 2013 Dec; 138(6):955-61. PubMed ID: 24521642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.
    Habtewold A; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Burhenne J; Aklillu E
    Pharmacogenomics; 2015; 16(10):1047-64. PubMed ID: 25831219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries.
    Maartens G; Decloedt E; Cohen K
    Antivir Ther; 2009; 14(8):1039-43. PubMed ID: 20032533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.
    Sinha S; Gupta K; Tripathy S; Dhooria S; Ranjan S; Pandey RM
    BMC Infect Dis; 2017 Dec; 17(1):761. PubMed ID: 29228918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.
    Rajesh L; Karunaianantham R; Narayanan PR; Swaminathan S
    AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1179-85. PubMed ID: 19895208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.